Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC424 in Myelofibrosis (China, Phase II)
CTR20130864Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), sponsored by Novartis. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on CTR20130864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130864.